Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

6 articles matching "immune system"

ResearchPUBMED2 days ago

Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases.

Scientists are studying a new type of medicine made from circular RNA, which is RNA shaped like a circle instead of a line. Because of their circular shape, these medicines may stay in the body longer and work better than current RNA medicines. Researchers are testing these circular RNA medicines to treat cancer, immune system diseases, and rare diseases.

WHY IT MATTERSCircular RNA therapeutics could eventually offer longer-lasting treatments for rare diseases with fewer doses needed, but patients should know that claims about safety and effectiveness vary depending on how the medicine is made—there's no one-size-fits-all answer yet.
Good to knowRead →
ResearchPUBMEDApr 14

Rare genetic diseases associated with G-quadruplex-induced replication stress.

Scientists have discovered that certain rare genetic diseases are caused by mutations in genes that help cells copy their DNA. These genes normally produce proteins that untangle special twisted DNA structures called G-quadruplexes that get in the way during copying. When these proteins don't work properly, cells can't copy their DNA correctly, leading to problems like weak immune systems, slow growth, birth defects, and increased cancer risk.

WHY IT MATTERSUnderstanding which genes cause these G-quadruplex problems could help doctors diagnose patients with unexplained immunodeficiency, growth delays, or birth defects, and may eventually lead to targeted treatments for these currently untreatable conditions.
Good to knowRead →
ResearchPUBMEDApr 1

Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).

Researchers studied whether the amount of cancer in a patient's body before treatment affects how well two immunotherapy drugs work together. They looked at 722 patients with rare cancers who received nivolumab and ipilimumab (two drugs that help the immune system fight cancer). The study wanted to understand if patients with smaller tumors do better than those with larger tumors when treated with these combination drugs.

WHY IT MATTERSIf baseline tumor size predicts treatment response in rare cancers, doctors could better counsel patients on expected outcomes and identify which patients might benefit most from this dual immunotherapy approach before starting treatment.
💬 Ask your doctorrare cancersultrarare malignanciesRead →
ResearchPUBMEDMar 26

Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

This study looked at how long it takes to diagnose APDS, a very rare immune system disorder that affects only 1-2 people per million. Researchers interviewed patients and doctors in Austria, Germany, and Switzerland and found that people typically wait several years before getting a correct diagnosis because the disease is so uncommon and looks different in different people.

WHY IT MATTERSPatients with APDS face years of diagnostic delay due to the disease's rarity and variable symptoms — understanding these barriers could help doctors recognize APDS faster and reduce the time families spend seeking answers.
💬 Ask your doctorActivated PI3 kinase delta syndrome (APDS)Primary immunodeficiencyRead →
ResearchCLINICALTRIALSMar 26

Trial Now Recruiting: Collection of Biological Samples From Patients With Rare Neurological Diseases (NCT04698421)

Researchers at a hospital in France are collecting biological samples (like blood) from 1,000 patients with rare nervous system diseases that may be caused by the immune system attacking the body. These samples will help scientists find new ways to diagnose and treat these diseases by identifying special markers in the blood that show disease activity.

WHY IT MATTERSIf you have a rare autoimmune neurological disease, participating in this sample collection could help researchers discover new biomarkers and treatments specifically for conditions like yours.
You can act on thisAutoimmune neurological diseasesRare nervous system diseasesRead →
ResearchCLINICALTRIALSMar 26

Trial Completed: Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 (NCT02116764)

Researchers completed a study following 137 patients with Chronic Granulomatous Disease (CGD), a rare immune system disorder. The study compared patients who received a bone marrow transplant (a procedure to replace damaged blood-forming cells) to patients who received standard medical care instead. This research helps doctors understand which treatment approach works best for CGD patients.

WHY IT MATTERSThis completed analysis provides real-world evidence comparing bone marrow transplant outcomes to standard care for CGD patients, which can help your doctor recommend the most effective treatment strategy for your specific situation.
💬 Ask your doctorChronic Granulomatous DiseaseRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases